Orphanet: Ricerca semplice

Cerca una sperimentazione clinica

Altra/e opzione/i di ricerca

200 Risultato/i

Sperimentazioni cliniche nazionali

EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - AU Institution: Information not provided - AU

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis Having Chronic Inflammation (Phase 1-2) - AT Institution: Information not provided - AT

Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2) Institution: Information not provided - AT

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept St. Michael's Hospital Keenan Research Centre

VISUAL III: A multicenter open-label study of the long-term safety and efficacy of the human anti-TNF monoclonal antibody adalimumab in subjects with non-infectious intermediate-, posterior-, or pan-uveitis (phase III) - FR Institution: Information not provided - FR

BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant Service de génétique

NOVASED: Efficiency Clinical Study of NOVATEX MEDICAL Compression Garments in Patients With Ehlers-Danlos Syndrome. CHU de Nancy - Hôpitaux de Brabois Service de médecine interne et immunologie clinique

Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial - FR Hôpital Necker-Enfants Malades Service de Génétique Moléculaire

ABASARC: Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis Klinik für Pneumologie am Universitätsklinikum Freiburg Klinik für Pneumologie

THALI-HHT: Efficacia del Talidomide nel trattamento della Telangiectasia emmorragica ereditaria - IT Fondazione IRCCS Policlinico San Matteo Clinica Medica III

An Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal Bleeding Radboudumc - Radboud universitair medisch centrum Afdeling Maag-, Darm- en Leverziekten

EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - PT Institution: Information not provided - PT

Azithromycin a Treatment for Pulmonary Sarcoidosis (CAPS) Hull York Medical School Respiratory Medicine Clinical Trials Unit

A Comparison of Two Wrist-worn Accelerometer Devices for the Measurement of Activity in Sarcoidosis Patients University of East Anglia HQ University of East Anglia

A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy Novartis Pharmaceuticals Medical Collaboration Centre

Calciphyx: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis - ES Institution: Information not provided - ES

A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis -GB Institution: Information not provided - US

Very low doses of Rituximab for off-label treatment - a Pilot Trial (Phase 2) Institution: Information not provided - AT

Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS) (Phase 2) - AT Institution: Information not provided - AT

An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD) (Phase 3) - AT Institution: Information not provided - AT

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis (Phase 2) - AT Institution: Information not provided - AT

BRAVE I: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus - AT Institution: Information not provided - AT

SLE-BRAVE-X: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE) - AT Institution: Information not provided - AT

TWINSS: A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjögren's Syndrome (Phase 2) - AT Institution: Information not provided - AT

PHOENYCS GO: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (Phase 3) - AT Institution: Information not provided - AT

Siccalkervis: Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome (Phase 4) Krankenhaus Hietzing Augenabteilung

SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE Ghent University Hospital - UZ Gent Department of Rheumatology

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE UZ Leuven - Campus Gasthuisberg UZ Leuven

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR Institution: Information not provided - FR

MSC: Treatment of Refractory Severe Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells - (Phase I-II) - FR CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire

MSC-LES: Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire

AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR CHU de Limoges - Hôpital Dupuytren Service d'hématologie clinique et de thérapie cellulaire

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - DE Zentrum für Innere Medizin (Krehl-Klinik) Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - DE Klinikum der Johann Wolfgang Goethe-Universität Frankfurt

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - DE Medizinische Hochschule Hannover Klinik für Nieren- und Hochdruckerkrankungen

SENSCIS (TM) Extension: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - DE Medizinische Hochschule Hannover Klinik für Pneumologie

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - DE Universitätsklinikum Essen

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - FR Universitätsklinikum Münster

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - DE Universitätsmedizin Mainz

A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus - JP Institution: Information not provided - JP

BRAVE II: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - JP Eli Lilly Japan K.K.

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE St. Vincent's University Hospital CF Clinic

Studio di fase 1/2 in aperto su Melflufen e Desametasone in pazienti con Amiloidosi AL che seguono almeno una precedente linea di terapia - IT Institution: Information not provided - IT

Studio multicentrico randomizzato di fase III del Melphalan e Dexamethasone (MDex) vs Bortezomib, Melphalan e Dexamethasone (BMDex) nel trattamento di pazienti con Amiloidosi. Fondazione IRCCS Policlinico San Matteo Laboratorio di Biotecnologie e Tecnologie Biomediche

Studio randomizzato di fase II/III di doxiciclina rispetto alla terapia di supporto standard nei pazienti con amiloidosi cardiaca AL di nuova diagnosi sottoposti a terapia a base di bortezomib - IT Fondazione IRCCS Policlinico San Matteo Dipartimento di Medicina Molecolare

ASTIS: Sperimentazione multicentrica di trapianto autologo di cellule staminali in pazienti affetti da Sclerodermia (Fase III) AOU Careggi Dipartimento di Biomedicina

Studio controllato randomizzato per testare l'efficacia della terapia del benessere in pazienti con sclerosi sistemica Università degli studi di Firenze Dipartimento di Scienze della Salute

The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II) UMC Utrecht - Universitair Medisch Centrum Utrecht Afdeling Nefrologie

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis (Phase I) Hospital de Santo António - Centro Hospitalar do Porto Unidade Clínica de Paramiloidose

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis (Phase II/III) Hospital de Santo António - Centro Hospitalar do Porto Unidade Clínica de Paramiloidose

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis (Phase II/III) Hospital de Sta. Maria - Centro Hospitalar de Lisboa Norte, EPE. Serviço de Neurologia

A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud's phenomenon Royal National Hospital for Rheumatic Disease Department of Rheumatology

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis-GB Addenbrooke's Hospital Addenbrookes Hospital

A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis - UK Institution: Information not provided - UK

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)GB Institution: Information not provided - UK

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis - UKUK Queen Elizabeth Hospital

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant (Phase III) - ES Hospital Juan Ramón Jiménez

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - ES Hospital Clínic de Barcelona Servicio de Hematología

ReDox: A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ES Hospital Clínic de Barcelona Servicio de Hematología

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Universitari Vall d'Hebron Servicio de Medicina Interna

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital de la Santa Creu i Sant Pau Servicio de Medicina Interna

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant (Phase III) - ES Hospital Universitari de Bellvitge

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Universitario Doctor Peset

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Universitario y Politécnico La Fe

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Álvaro Cunqueiro

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - ES Institution: Information not provided - ES

A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus - ES Institution: Information not provided - ES

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital General Universitario Gregorio Marañón

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Universitario 12 de Octubre

A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects Alnylam Pharmaceuticals, Inc.

A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis University of Washington

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - CH Institution: Information not provided - CH

CARDIO-TTRansform: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - AT Institution: Information not provided - AT

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) - AT Institution: Information not provided - AT

Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy (Phase II) Ghent University Hospital - UZ Gent Department of Rheumatology

NOVESA study: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis - BE Ghent University Hospital - UZ Gent Department of Rheumatology

EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - AU
Institution: Information not provided - AU

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis Having Chronic Inflammation (Phase 1-2) - AT
Institution: Information not provided - AT

Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2)
Institution: Information not provided - AT

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
St. Michael's Hospital

Keenan Research Centre

VISUAL III: A multicenter open-label study of the long-term safety and efficacy of the human anti-TNF monoclonal antibody adalimumab in subjects with non-infectious intermediate-, posterior-, or pan-uveitis (phase III) - FR
Institution: Information not provided - FR

BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study
CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant

Service de génétique

NOVASED: Efficiency Clinical Study of NOVATEX MEDICAL Compression Garments in Patients With Ehlers-Danlos Syndrome.
CHU de Nancy - Hôpitaux de Brabois

Service de médecine interne et immunologie clinique

Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial - FR
Hôpital Necker-Enfants Malades

Service de Génétique Moléculaire

ABASARC: Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis
Klinik für Pneumologie am Universitätsklinikum Freiburg

Klinik für Pneumologie

THALI-HHT: Efficacia del Talidomide nel trattamento della Telangiectasia emmorragica ereditaria - IT
Fondazione IRCCS Policlinico San Matteo

Clinica Medica III

EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - PT
Institution: Information not provided - PT

Azithromycin a Treatment for Pulmonary Sarcoidosis (CAPS)
Hull York Medical School

Respiratory Medicine Clinical Trials Unit

A Comparison of Two Wrist-worn Accelerometer Devices for the Measurement of Activity in Sarcoidosis Patients
University of East Anglia HQ

University of East Anglia

A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy
Novartis Pharmaceuticals

Medical Collaboration Centre

Calciphyx: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis - ES
Institution: Information not provided - ES

A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis -GB
Institution: Information not provided - US

Very low doses of Rituximab for off-label treatment - a Pilot Trial (Phase 2)
Institution: Information not provided - AT

Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS) (Phase 2) - AT
Institution: Information not provided - AT

An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD) (Phase 3) - AT
Institution: Information not provided - AT

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis (Phase 2) - AT
Institution: Information not provided - AT

BRAVE I: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus - AT
Institution: Information not provided - AT

SLE-BRAVE-X: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE) - AT
Institution: Information not provided - AT

TWINSS: A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjögren's Syndrome (Phase 2) - AT
Institution: Information not provided - AT

PHOENYCS GO: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (Phase 3) - AT
Institution: Information not provided - AT

Siccalkervis: Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome (Phase 4)
Krankenhaus Hietzing

Augenabteilung

SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE
Ghent University Hospital - UZ Gent

Department of Rheumatology

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
UZ Leuven - Campus Gasthuisberg

UZ Leuven

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR
Institution: Information not provided - FR

MSC: Treatment of Refractory Severe Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells - (Phase I-II) - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis

Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire

MSC-LES: Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis

Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire

AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR
CHU de Limoges - Hôpital Dupuytren

Service d'hématologie clinique et de thérapie cellulaire

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - DE
Zentrum für Innere Medizin (Krehl-Klinik)

Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - DE
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - DE
Medizinische Hochschule Hannover

Klinik für Nieren- und Hochdruckerkrankungen

SENSCIS (TM) Extension: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - DE
Medizinische Hochschule Hannover

Klinik für Pneumologie

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - DE
Universitätsklinikum Essen

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - FR
Universitätsklinikum Münster

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - DE
Universitätsmedizin Mainz

A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus - JP
Institution: Information not provided - JP

BRAVE II: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - JP
Eli Lilly Japan K.K.

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE
St. Vincent's University Hospital

CF Clinic

Studio di fase 1/2 in aperto su Melflufen e Desametasone in pazienti con Amiloidosi AL che seguono almeno una precedente linea di terapia - IT
Institution: Information not provided - IT

Studio multicentrico randomizzato di fase III del Melphalan e Dexamethasone (MDex) vs Bortezomib, Melphalan e Dexamethasone (BMDex) nel trattamento di pazienti con Amiloidosi.
Fondazione IRCCS Policlinico San Matteo

Laboratorio di Biotecnologie e Tecnologie Biomediche

Studio randomizzato di fase II/III di doxiciclina rispetto alla terapia di supporto standard nei pazienti con amiloidosi cardiaca AL di nuova diagnosi sottoposti a terapia a base di bortezomib - IT
Fondazione IRCCS Policlinico San Matteo

Dipartimento di Medicina Molecolare

ASTIS: Sperimentazione multicentrica di trapianto autologo di cellule staminali in pazienti affetti da Sclerodermia (Fase III)
AOU Careggi

Dipartimento di Biomedicina

Studio controllato randomizzato per testare l'efficacia della terapia del benessere in pazienti con sclerosi sistemica
Università degli studi di Firenze

Dipartimento di Scienze della Salute

The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II)
UMC Utrecht - Universitair Medisch Centrum Utrecht

Afdeling Nefrologie

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis (Phase I)
Hospital de Santo António - Centro Hospitalar do Porto

Unidade Clínica de Paramiloidose

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis (Phase II/III)
Hospital de Santo António - Centro Hospitalar do Porto

Unidade Clínica de Paramiloidose

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis (Phase II/III)
Hospital de Sta. Maria - Centro Hospitalar de Lisboa Norte, EPE.

Serviço de Neurologia

A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud's phenomenon
Royal National Hospital for Rheumatic Disease

Department of Rheumatology

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis-GB
Addenbrooke's Hospital

Addenbrookes Hospital

A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis - UK
Institution: Information not provided - UK

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)GB
Institution: Information not provided - UK

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis - UKUK
Queen Elizabeth Hospital

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant (Phase III) - ES
Hospital Juan Ramón Jiménez

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - ES
Hospital Clínic de Barcelona

Servicio de Hematología

ReDox: A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ES
Hospital Clínic de Barcelona

Servicio de Hematología

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitari Vall d'Hebron

Servicio de Medicina Interna

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital de la Santa Creu i Sant Pau

Servicio de Medicina Interna

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant (Phase III) - ES
Hospital Universitari de Bellvitge

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario Doctor Peset

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario y Politécnico La Fe

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Álvaro Cunqueiro

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - ES
Institution: Information not provided - ES

A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital General Universitario Gregorio Marañón

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario 12 de Octubre

A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects
Alnylam Pharmaceuticals, Inc.

A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
University of Washington

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - CH
Institution: Information not provided - CH

CARDIO-TTRansform: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - AT
Institution: Information not provided - AT

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) - AT
Institution: Information not provided - AT

Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy (Phase II)
Ghent University Hospital - UZ Gent

Department of Rheumatology

NOVESA study: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis - BE
Ghent University Hospital - UZ Gent

Department of Rheumatology

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy - FR
CHU Paris-Sud - Hôpital de Bicêtre

Service de neurologie - CRMR NNERf

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study (Phase III) - FR
CHU Paris-Sud - Hôpital de Bicêtre

Service de neurologie - CRMR NNERf

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - FR
CHU Paris-Sud - Hôpital de Bicêtre

Service de neurologie - CRMR NNERf

RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis -DE-
Universitätsklinikum Freiburg

RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis -DE-
Universitätsklinikum Heidelberg